Literature DB >> 19713119

Clinical outcome of the Fontan operation in patients with impaired ventricular function.

Yasuhiro Kotani1, Shingo Kasahara, Yasuhiro Fujii, Ko Yoshizumi, Yu Oshima, Shin-Ichi Otsuki, Teiji Akagi, Shunji Sano.   

Abstract

OBJECTIVE: Although a staged Fontan strategy allows for an excellent outcome in high-risk patients, an impaired ventricular function remains a significant factor of early/late mortality and morbidity. This study evaluated the clinical outcome of the Fontan operation in patients with impaired ventricular function.
METHODS: A retrospective review was performed on 217 patients who had undergone the Fontan operation between 1991 and 2007.
RESULTS: Twenty-nine (13%) of the 217 patients had an impaired ventricular function (ejection fraction (EF) <50%). The median age at the time of the operation was 3 (range: 1-31 years) years. There were five adult patients. The ventricular morphology was right in 20 patients (including five hypoplastic left heart syndrome (HLHS)) and others (left and two-ventricle) in nine patients. Heterotaxy syndrome was present in eight patients. Previous surgical interventions included bidirectional Glenn anastomoses in 24, modified Blalock-Taussig shunts in two and pulmonary artery banding in two. The preoperative EF was 43+/-6%. Significant (moderate or severe) atrioventricular valve regurgitation was noted in four patients. The percutaneous oxygen saturation (SpO(2)) was 82+/-5%. The pulmonary artery pressure and pulmonary artery index were 11+/-3 mmHg and 296+/-102 mm(2)m(-2), respectively. All 29 patients underwent the Fontan operation without any early mortality. There were two late mortalities and two re-operations. EF was maintained at 59+/-15% at a median follow-up of 7.5 (range: 1-19) years. The percent normal systemic ventricular end-diastolic volume decreased from 174+/-95% to 124+/-39% (p<0.05). The SpO(2) increased to 92+/-2%. The mean cardiothoracic ratio in chest X-ray and B-type natriuretic peptide were 51% (range: 35-68%) and 22 pgml(-1) (range: 9-382 pgml(-1)), respectively. Three patients developed congestive heart failure, seven had arrhythmia and two developed protein-losing enteropathy. The New York Heart Association (NYHA) class functional class is I in 21 patients, II in five and III in one.
CONCLUSIONS: Acceptable clinical outcomes were observed at an intermediate follow-up of the Fontan operation in patients with an impaired ventricular function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19713119     DOI: 10.1016/j.ejcts.2009.04.042

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  4 in total

1.  Sickle Cell Disease with Cyanotic Congenital Heart Disease: Long-Term Outcomes in 5 Children.

Authors:  Glen J Iannucci; Olufolake A Adisa; Matthew E Oster; Michael McConnell; William T Mahle
Journal:  Tex Heart Inst J       Date:  2016-12-01

2.  Risk factors for failed staged palliation after bidirectional Glenn in infants who have undergone stage one palliation.

Authors:  Kevin G Friedman; Joshua W Salvin; David Wypij; Yared Gurmu; Emile A Bacha; David W Brown; Peter C Laussen; Mark A Scheurer
Journal:  Eur J Cardiothorac Surg       Date:  2011-03-05       Impact factor: 4.191

3.  Impact of Initial Shunt Type on Echocardiographic Indices in Children After Single Right Ventricle Palliations.

Authors:  Peter C Frommelt; Chenwei Hu; Felicia Trachtenberg; Jeanne Marie Baffa; Richard J Boruta; Shahryar Chowdhury; James F Cnota; Andreea Dragulescu; Jami C Levine; Jimmy Lu; Laura Mercer-Rosa; Thomas A Miller; Amee Shah; Timothy C Slesnick; Gary Stapleton; Jessica Stelter; Pierre Wong; Jane W Newburger
Journal:  Circ Cardiovasc Imaging       Date:  2019-02       Impact factor: 7.792

4.  Right ventricular systolic function in hypoplastic left heart syndrome: a comparison of velocity vector imaging and magnetic resonance imaging.

Authors:  Hanna Ruotsalainen; Hannah Bellsham-Revell; Aaron Bell; Jaana Pihkala; Tiina Ojala; John Simpson
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-08-30       Impact factor: 6.875

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.